title: LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
abstract: Ninety patients with advanced prostatic cancer (15 with stage B, 23 with stage C, and 52 with stage D) were randomized to receive 0.9, 1.8, or 3.6 mg, respectively, of Zoladex depot subcutaneous injection every 28 days for 12 weeks. The serum levels of LH, FSH, and testosterone were elevated after the first injection, and followed by a significant decrease. The suppression of testosterone levels in the blood to castrate levels was observed in all patients except two treated with 0.9 mg. Objective response (CR and PR) was seen in 63.6% (0.9 mg), 47.8% (1.8 mg), and 68% (3.6 mg) of patients according to the Japanese Prostatic Group Criteria. Subjective improvement (performance status, analgesic consumption) was also observed in 75-88% of patients but without a statistically significant difference between each dose group. Only minor adverse effects were found during the treatments. The drug was detected dose dependently in the blood by radioimmunoassay. These results suggest that endocrine therapy with Zoladex depot in doses of 3.6 mg subcutaneously every 4 weeks is a useful alternative to surgical castration in patients with prostatic cancer.
authors.affiliation: Centre for Adult Diseases, Osaka University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kotake
authors.forename: M
authors.initials: M
authors.lastname: Usami
authors.forename: T
authors.initials: T
authors.lastname: Sonoda
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.forename: E
authors.initials: E
authors.lastname: Okajima
authors.forename: M
authors.initials: M
authors.lastname: Osafune
authors.forename: K
authors.initials: K
authors.lastname: Isurugi
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D007564:Japan; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D012074:Remission Induction; D013739:Testosterone / Q000097:blood
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin